Healthcare - Biotechnology - NASDAQ - US
$ 36.45
-0.274 %
$ 2.71 B
Market Cap
-7.81
P/E
CASH FLOW STATEMENT
-223 M
OPERATING CASH FLOW
34.8 M
INVESTING CASH FLOW
297 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
SpringWorks Therapeutics, Inc.
| Net Income | -325 M |
| Depreciation & Amortization | 1.67 M |
| Capital Expenditures | -7.38 M |
| Stock-Based Compensation | 94.5 M |
| Change in Working Capital | -583 K |
| Others | 15.3 M |
| Free Cash Flow | -230 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (325.1) | (277.4) | (173.9) | (45.6) | (58.3) | (17.8) | (4.6) |
| Depreciation & Amortization | 1.7 | 0.8 | 0.5 | 0.3 | 0.2 | 17 K | 3.18 K |
| Deferred Income Tax | 0 | 0 | 1.0 | 0.6 | 0 | 0 | 0 |
| Stock Based Compensation | 94.5 | 73.0 | 38.4 | 10.0 | 3.1 | 1.1 | 0 |
| Other Operating Activities | 6.7 | 4.0 | 1.0 | 1.0 | 2.6 | 0.6 | 1.7 |
| Change in Working Capital | (0.6) | 38.1 | 5.1 | 1.3 | 4.9 | 2.0 | 0.4 |
| Cash From Operations | (222.8) | (161.6) | (127.9) | (32.2) | (47.4) | (14.7) | (2.2) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (7.4) | (10.2) | (2.0) | (0.6) | (0.7) | (0.3) | 44 K |
| Other Items | 42.1 | (205.4) | 85.6 | (418.2) | (3.6) | 0 | 0 |
| Cash From Investing Activities | 34.8 | (215.6) | 83.6 | (418.8) | (4.3) | (0.3) | 44 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | (2.8) | (1.3) | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.1 | 2.0 | 1.2 | 0.9 | 164.0 | 50.4 | 12.6 |
| Cash From Financing Activities | 296.6 | 340.7 | 1.2 | 270.5 | 333.7 | 50.4 | 12.6 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 108.6 | (36.5) | (43.1) | (180.5) | 282.0 | 35.4 | 10.3 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (230.2) | (171.8) | (129.9) | (32.8) | (48.1) | (15.0) | (2.3) |